No products in the cart.
Pre-made Prezalumab benchmark antibody ( Whole mAb, anti-ICOSLG/B7RP1 therapeutic antibody, Anti-B7-H2/B7H2/B7h/CD275/GL50/ICOS-L/ICOSL/LICOS Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-456
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Prezalumab biosimilar, Whole mAb, Anti-ICOSLG/B7RP1 Antibody: Anti-B7-H2/B7H2/B7h/CD275/GL50/ICOS-L/ICOSL/LICOS therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Prezalumab is an IgG2 type monoclonal antibody designed to bind to ICOSL, inhibiting the interaction between ICOSL and ICOS and reducing the body’s autoimmune response.
| Products Name (INN Index) | Pre-Made Prezalumab biosimilar, Whole mAb, Anti-ICOSLG/B7RP1 Antibody: Anti-B7-H2/B7H2/B7h/CD275/GL50/ICOS-L/ICOSL/LICOS therapeutic antibody |
|---|---|
| INN Name | Prezalumab |
| Target | ICOSLG |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 6x4t:BE:DF |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Amgen,MedImmune |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Cutaneous lupus erythematosus,Psoriasis,Sjogren's syndrome,Systemic lupus erythematosus |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ICOSLG |
| Package |
Previous slide
Next slide
